603229 奥翔药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.05914.09517.33312.2549.800
总资产报酬率 ROA (%)6.0639.64111.3309.0617.658
投入资产回报率 ROIC (%)6.88211.43313.57310.3266.951

边际利润分析
销售毛利率 (%)59.80555.04851.50154.78756.434
营业利润率 (%)42.26635.60733.70828.11223.608
息税前利润/营业总收入 (%)39.40131.47927.93928.98927.163
净利润/营业总收入 (%)36.52231.08630.78625.61521.218

收益指标分析
经营活动净收益/利润总额(%)101.09796.38298.04995.144100.579
价值变动净收益/利润总额(%)1.5180.2412.4737.317-4.871
营业外收支净额/利润总额(%)-0.263-0.021-0.725-0.477-1.168

偿债能力分析
流动比率 (X)2.7372.1721.5251.9244.018
速动比率 (X)2.1561.6991.0951.4653.238
资产负债率 (%)22.11627.44336.89331.78318.442
带息债务/全部投入资本 (%)11.43014.95120.26320.519--
股东权益/带息债务 (%)762.861558.661384.038384.4511,150.875
股东权益/负债合计 (%)352.153264.394171.056214.630442.250
利息保障倍数 (X)-14.308-7.639-5.05628.6697.095

营运能力分析
应收账款周转天数 (天)80.30458.96647.33435.3250.000
存货周转天数 (天)330.611336.194273.793303.0180.000